Reduced expression of the long non-coding RNA AI364715 in gastric cancer and its clinical significance

Zhu, Shengqian; Mao, Jinqin; Shao, Yongfu; Chen, Fang; Zhu, Xiaoqin; Xu, Dingli; Zhang, Xinjun; Guo, Junming

doi:10.1007/s13277-015-3543-7

Cited by 23 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, decreased expression of ncRuPAR significantly correlates with tumor invasion depth, lymph node metastasis, distant metastasis, tumor size and TNM stage in gastric cancer . A downregulation in the expression of AI364715, GACAT1, and GACAT2 in gastric cancer tissues; PCAT29 in prostate cancer; AC026166.2–001 and RP11‐169D4.1–001 in larynx squamous cell carcinoma; lncRNA‐LET and MEG3 in GBC tissues could also be used as a prognostic marker. The epigenetic changes in lncRNAs could also predict prognosis of the disease.…”

Section: Lncrnas In Cancer Prognosismentioning

confidence: 99%

Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets

Gupta

Tripathi

2016

Intl Journal of Cancer

432

260

View full text Add to dashboard Cite

Because of high specificity and easy detection in the tissues, serum, plasma, urine and saliva, interest in exploring the potential of long non-coding RNAs (lncRNAs) in cancer patients continues to increase. LncRNAs have shown potential as a biomarker in the diagnosis and prognosis of bladder cancer, prostate cancer, gastric cancer, pancreatic cancer, breast cancer and many other cancer types. Some lncRNAs have also been used as adjunct to improve the specificity and sensitivity of existing biomarkers. The molecular tools such as RNA-seq, RNA-FISH, ic-SHAPE and quantitative real-time PCR have been used for examining the lncRNAs' potential. Some lncRNAs such as PCA3 is now routinely used in the clinic for the diagnosis of prostate cancer. Single nucleotide polymorphisms (SNPs) in lncRNAs can also be used as a predictor of cancer risk. Although ongoing studies continue to unravel the underlying mechanism, some lncRNAs have been used as therapeutic targets for the selective killing of cancer cells in patients. Thus lncRNAs are emerging as convenient and minimally invasive diagnostic/prognostic markers, and also as therapeutic target. Companies such as the Curna Inc., MiNA Therapeutics Ltd. and RaNA Therapeutics Inc. have been taking steps to develop lncRNA based strategies against cancer. In this review, we discuss the potential of lncRNAs as biomarkers and therapeutic targets in cancer patients.

show abstract

Section: Lncrnas In Cancer Prognosismentioning

confidence: 99%

Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets

Gupta

Tripathi

2016

Intl Journal of Cancer

432

260

View full text Add to dashboard Cite

show abstract

“…Advances in the depth and quality of transcript me sequencing have revealed a range of lncRNAs classes dysregulated in various human diseases, particularly cancer (9)(10)(11). H19 is a member of a highly-conserved cluster of imprinted genes, and was the first lncRNA to be associated with cancer (12). Previous studies have indicated that H19 exhibits dysregulated expression in GC (13,14), hepatocellular carcinoma (15), bladder cancer (16), breast cancer (17) and esophageal cancer (18), and that itmay cause tumor promoting and suppressing effects (19).…”

Section: Introductionmentioning

confidence: 99%

Downregulated long non‑coding RNA TCONS_00068220 upregulates apoptosis in gastric cancer cells

et al. 2017

View full text Add to dashboard Cite

Abstract. Long non-coding RNAs (lncRNAs) are emerging as a fundamental class of biological effect or molecules that perform pivotal functions in the regulation of the genome. With advances in bioinformatics and genomics, extensive identification and characterization of lncRNAs is now possible. They regulate cellular growth, differentiation and apoptosis. Dysregulation of lncRNAs has been associated with numerous types of human cancer. In the present study, the expression profile of differentially expressed genes (DEGs) and lncRNAs in gastric cancer (GC) samples and normal tissue samples was evaluated with bioinformatics. The biological functions of the predicted lncRNA TCONS_00068220 were focused on; the DEGs co-expressed with TCONS_00068220 were enriched in cancer-associated pathways. TCONS_00068220 was demonstrated to be upregulated in GC tissues and cell lines compared with normal controls. In addition, an increased rate of apoptosis was observed in NCI-N87 cells following transfection with small interfering RNA against TCONS_00068220. These data suggest that TCONS_00068220 may be associated with the pathogenesis of GC, and it may serve as a potential therapeutic target.

show abstract

“…These results suggest that ncRuPAR may inhibit GC by regulating PAR1, serving as a potential marker for GC [70]. Another downregulated lncRNA in GC is AI364715, which was assessed in GC tissue, paired human healthy gastric mucosa and gastric precancerous lesions (dysplasia) tissue [71]. AI364715 expression was significantly more downregulated in GC than in noncancerous and dysplasia tissues, and closely linked to tumor size and differentiation, which suggests AI364715 as a potential biomarker for a GC diagnosis [71].…”

Section: Tissue Markersmentioning

confidence: 91%

Long non-coding RNAs in gastric cancer: mechanisms and potential applications

Riquelme¹,

Ili²,

Roa³

et al. 2016

Oncotarget

View full text Add to dashboard Cite

Gastric cancer is the third leading cause of cancer mortality worldwide. Unfortunately, most gastric cancer cases are diagnosed in an advanced, non-curable stage with a limited response to chemotherapy. Recent findings in gastric cancer-causing gene expression mechanisms, however, hold promise for the development of more effective diagnostic and treatment strategies. A novel mechanism for gene expression control mediated by long non-coding RNAs (lncRNAs) has been described, which have emerged as pivotal regulatory components orchestrating extensive cell processes and connections within eukaryotic cells. LncRNA-based mechanisms alter cell fates during development, and their deregulation underscores many human disorders, including gastric cancer. Recent studies have reported that several lncRNAs are aberrantly expressed and linked to the onset and progression of this malignancy. These lncRNAs have gained value for such clinical purposes as novel biomarkers and therapeutic targets; yet despite this potential, many issues remain in this rapidly growing field. This review summarizes the classification and role of lncRNAs, and provides an updated overview of the feasibility of lncRNAs as diagnostic and prognostic tools in clinical samples and as potential therapeutic targets in GC patients.

show abstract

Reduced expression of the long non-coding RNA AI364715 in gastric cancer and its clinical significance

Cited by 23 publications

References 29 publications

Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets

Potential of long non‐coding RNAs in cancer patients: From biomarkers to therapeutic targets

Downregulated long non‑coding RNA TCONS_00068220 upregulates apoptosis in gastric cancer cells

Long non-coding RNAs in gastric cancer: mechanisms and potential applications

Contact Info

Product

Resources

About